Free Trial
→ Buffett's Final Warning: 'The Dollar Is Going to Hell' (From Decentralized Masters) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$12.68
+2.5%		$11.79
$2.74
▼
$15.02
$3.89B1.416.08 million shs5.76 million shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$9.89
+5.1%		$12.66
$6.62
▼
$15.35
$949.87M1.35758,293 shs836,396 shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$17.30
+1.4%		$18.95
$5.95
▼
$21.27
$3.79B1.723.19 million shs2.12 million shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.57
-0.8%		$11.54
$6.28
▼
$13.11
$3.62B-0.17232,392 shs215,492 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-1.90%-3.59%+10.74%+100.81%+120.11%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-5.33%-13.03%-26.94%-23.68%+18.66%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-1.73%-4.96%-10.49%-11.93%+182.92%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-2.47%-4.23%-9.59%-1.66%+6.08%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$12.68
+2.5%		$11.79
$2.74
▼
$15.02
$3.89B1.416.08 million shs5.76 million shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$9.89
+5.1%		$12.66
$6.62
▼
$15.35
$949.87M1.35758,293 shs836,396 shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$17.30
+1.4%		$18.95
$5.95
▼
$21.27
$3.79B1.723.19 million shs2.12 million shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.57
-0.8%		$11.54
$6.28
▼
$13.11
$3.62B-0.17232,392 shs215,492 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-1.90%-3.59%+10.74%+100.81%+120.11%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-5.33%-13.03%-26.94%-23.68%+18.66%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-1.73%-4.96%-10.49%-11.93%+182.92%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-2.47%-4.23%-9.59%-1.66%+6.08%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.80
Moderate Buy$13.899.53% Upside
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.78
Moderate Buy$24.71149.89% Upside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.93
Moderate Buy$25.9249.81% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
2.80
Moderate Buy$20.5093.95% Upside

Current Analyst Ratings Breakdown

Latest MGTX, RLAY, ABCL, and TLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/12/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$18.00
10/11/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
10/8/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C) ➝ Hold (C+)
10/2/2026
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/29/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight$17.00
9/25/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$20.00
9/24/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageNeutral$16.00
9/24/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageNeutral$13.00
9/24/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageNeutral$16.00
9/23/2026
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform$22.00
9/22/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D-) ➝ Hold (C)
(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$66.17M58.76N/AN/A$3.23 per share3.93
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$397.50M2.39N/AN/A($0.07) per share-141.29
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$10.35M366.30N/AN/A$3.27 per share5.29
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$890.79M4.03$0.04 per share258.99$1.23 per share8.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.41M-$0.54N/AN/AN/A-248.83%-17.49%-12.36%11/9/2026 (Confirmed)
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$114.20M$0.7113.93N/AN/A19.87%283.85%29.39%11/12/2026 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$276.48M-$1.57N/AN/AN/AN/A-42.27%-38.67%11/5/2026 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-$7.12MN/AN/A39.15N/AN/AN/AN/AN/A

Latest MGTX, RLAY, ABCL, and TLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.46N/AN/AN/A$6.95 millionN/A
11/9/2026Q3 2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.1757N/AN/AN/A$6.25 millionN/A
11/5/2026Q3 2026
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.3964N/AN/AN/A$1.62 millionN/A
8/13/2026Q2 2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.4583$1.71+$2.1683$1.71$0.70 million$321.43 million
8/6/2026Q2 2026
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.3911-$0.41-$0.0189-$0.41$0.96 million$0.35 million
8/5/2026Q2 2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.1640-$0.18-$0.0160-$0.18$7.85 million$4.05 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
12.77
12.77
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.46
3.76
3.76
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
18.27
18.27
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1.16
2.01
1.85

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.40%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.40%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
5.04%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
562306.61 million219.53 millionOptionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
39396.04 million88.94 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
192219.14 million208.10 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
1,184339.89 millionN/AN/A

Recent News About These Companies

Dr Boreham’s crucible: Telix bets big on ITM as radiopharma consolidation gathers pace
 |  msn.comhttps://www.msn.com/en-au/money/markets/dr-boreham-s-crucible-telix-bets-big-on-itm-as-radiopharma-consolidation-gathers-pace/ar-AA2ejPaT
Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM
October 14 at 1:41 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/telix-highlights-pivotal-trials-prostate-050000423.html
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
October 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/09/3378032/33471/en/profound-medical-and-telix-pharmaceuticals-enter-co-education-agreement-to-advance-psma-informed-prostate-care.html
Telix to Host Capital Markets Day in Melbourne on November 4, 2026
October 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/telix-host-capital-markets-day-200000678.html
Telix Pharmaceuticals: Merger Bodes Well For Long-Term Plan
October 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952818-telix-pharmaceuticals-merger-bodes-well-for-long-term-plan
UBS thinks Telix Pharmaceuticals shares will go how high
October 8, 2026  |  msn.comhttps://www.msn.com/en-au/money/general/ubs-thinks-telix-pharmaceuticals-shares-will-go-how-high/ar-AA2dM53e
Telix Issues 15,000 New Shares From Conversion of Unquoted Securities
October 8, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TLPPF/pressreleases/4990450/telix-issues-15000-new-shares-from-conversion-of-unquoted-securities/
Australian Shares Flat; Telix Pharmaceuticals Launches US Commercial Availability of Brain Cancer Imaging Drug
October 7, 2026  |  au.finance.yahoo.comhttps://au.finance.yahoo.com/news/australian-shares-flat-telix-pharmaceuticals-053002876.html
Telix Adds 436,366 New Shares to ASX Listing
October 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TLPPF/pressreleases/4990452/telix-adds-436366-new-shares-to-asx-listing/
Telix Pharmaceuticals Reports Lapse of Conditional Equity Securities
October 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/TLPPF/pressreleases/4990448/telix-pharmaceuticals-reports-lapse-of-conditional-equity-securities/
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
October 6, 2026  |  taiwannews.com.twT
First U.S. Patient Receives Telix's Newly Approved Brain Cancer Imaging Drug
October 6, 2026  |  rttnews.comhttps://www.rttnews.com/3696803/first-u-s-patient-receives-telix-s-newly-approved-brain-cancer-imaging-drug.aspx
First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375287/0/en/first-patients-dosed-with-telix-s-fda-approved-brain-cancer-imaging-drug-pixclara-floretyrosine-f-18.html
Sidley Represents Telix Pharmaceuticals in Its US$1.65 Billion Merger With ITM
October 5, 2026  |  sidley.comS
IBA and Telix strengthen ties through agreement to distribute ARTMS’s QIS®
October 1, 2026  |  biospace.comB
IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372512/0/en/iba-and-telix-strengthen-ties-through-agreement-to-distribute-artms-s-qis.html
Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade
September 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2998180/wall-street-analysts-believe-telix-pharmaceuticals-limited-tlx-could-rally-83-42-here-s-is-how-to-trade?cid=cs-stocknewsapi-ft-fundamental_analysis|consensus_price_target-2998180
Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging
September 30, 2026  |  manilatimes.netM
Telix Pharmaceuticals wins FDA fast track for BiPASS prostate cancer imaging
September 30, 2026  |  msn.comhttps://www.msn.com/en-au/money/general/telix-pharmaceuticals-wins-fda-fast-track-for-bipass-prostate-cancer-imaging/ar-AA2ddYox
Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - Here's Why
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-telix-pharmaceuticals-nasdaq-tlx-sees-strong-trading-volume-heres-why-2026-09-28/
Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Now Rated "Buy" by Wall Street Brokerages
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-telix-pharmaceuticals-limited-nasdaq-tlx-stock-now-rated-buy-by-wall-street-brokerages-2026-09-28/

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$12.68 +0.31 (+2.51%)
Closing price 04:00 PM Eastern
Extended Trading
$12.68 0.00 (0.00%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$9.89 +0.48 (+5.10%)
Closing price 04:00 PM Eastern
Extended Trading
$9.89 0.00 (0.00%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$17.30 +0.24 (+1.41%)
Closing price 04:00 PM Eastern
Extended Trading
$17.69 +0.39 (+2.25%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$10.57 -0.08 (-0.75%)
Closing price 04:00 PM Eastern
Extended Trading
$10.48 -0.09 (-0.89%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas